Encompass Health (EHC)
(Delayed Data from NYSE)
$82.47 USD
-0.26 (-0.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $82.47 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EHC 82.47 -0.26(-0.31%)
Will EHC be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EHC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EHC
Why Encompass Health (EHC) is a Top Momentum Stock for the Long-Term
Why Encompass Health (EHC) is a Top Momentum Stock for the Long-Term
EHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Encompass Health Corporation (EHC) Hit a 52 Week High, Can the Run Continue?
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
Why Encompass Health (EHC) is a Top Growth Stock for the Long-Term
Other News for EHC
Encompass Health price target raised by $10 at Raymond James, here's why
Encompass Health Corp (EHC) Q1 2024 Earnings Call Transcript Highlights: Strong Performance and ...
Analysts Offer Insights on Healthcare Companies: Encompass Health (EHC), Universal Health (UHS) and Viking Therapeutics (VKTX)
Encompass Health’s Growth Trajectory Spurs Buy Rating and Increased Price Objective
Encompass Health price target raised by $2 at Mizuho, here's why